<DOC>
	<DOCNO>NCT02957552</DOCNO>
	<brief_summary>Since introduction calcineurin-based immunosuppression , patient graft survival pediatric liver transplantation ( LT ) improve significantly . However , contrast , calcineurin inhibitor ( CNI ) toxicity lead significant morbidity impair quality life recipient . Moreover , CNI prevent long-term allograft inflammation fibrosis . Mesenchymal stem ( stromal ) cell ( MSC ) potent immunomodulatory property potentially promote allograft tolerance ameliorate toxicity exposure high dose CNI . Previous trial non-solid organ transplant indication show excellent safety profile intravenous MSC application . The MYSTEP1 trial aim investigate safety benefit portal intravenous MSC infusion pediatric LT .</brief_summary>
	<brief_title>Safety Tolerance Immunomodulating Therapy With Donor-specific MSC Pediatric Living-Donor Liver Transplantation</brief_title>
	<detailed_description />
	<criteria>1 . Written informed consent ( patient , parent / legal guardian ) 2. age ≥ 8 week ≤ 18 year 3. undergo live donor liver transplantation chronic terminal liver failure 4 . Body weight &gt; 5kg 1 . No suitability livingdonor 2 . Pregnant breastfeed 3 . If appropriate : use adequate contraception 4 . Acute liver failure ; highly urgent transplantation 5 . Receiving form solid organ retransplantation 6 . MultiOrganTransplantations 7 . Active autoimmune disease 8 . Preexisting renal failure eGFR &lt; 50 ml/min/1.73 m2 require hemodialysis 9 . Reduced pulmonary function ( lung function test child older 6 year : FEV1 FVC &lt; 70 % ageappropriate norm ) clinical suspicion pulmonary disease affect patient 's physical performance , require invasive noninvasive mechanical ventilation . 10 . History pulmonary embolism 11 . Pulmonary hypertension / right ventricular load echocardiography 12 . Cardiac function : leave ventricular shorten fraction ( FS ) &lt; 25 % 13 . Clinically significant systemic infection 14 . Critical care treatment like mechanical ventilation , dialysis vasopressor agent . 15 . HIV seropositive , HTLV seropositive , Hepatitis B/C seropositive 16 . Hepatobiliary malignancy history extrahepatic malignancy 17 . Thrombophilia 18 . BuddChiari syndrome 19 . Preexistent thrombosis portal vein 20 . Dopplersonographic evidence relevant portosystemic shunt , like persistent Ductus Venosus 21 . Cold ischemia time &gt; 90 min 22 . Known abuse drug alcohol 23 . Known allergy DMSO</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>